FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hans-Henrik Parving

Research Profile

Disorders

Physiology

Chemicals & Drugs

Concepts & Ideas

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
G Andrésdóttir; Stephan J.L. Bakker; H P Hansen; Hans-Henrik Parving; Peter Rossing
Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes.
Dick De Zeeuw; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Pablo E Pergola; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; David G Warnock; Janet Wittes; Rajiv Agarwal; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Glenn M Chertow
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
Anne Julie Overgaard; Hans-Henrik Parving; Peter Hovind; James N McGuire; Peter Rossing; Flemming Pociot
Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hans-Henrik Parving (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: G Andrésdóttir; Stephan J.L. Bakker; H P Hansen; Hans-Henrik Parving; Peter Rossing
Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2013;30(5):563-6.
2013: Dick De Zeeuw; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Pablo E Pergola; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; David G Warnock; Janet Wittes; Rajiv Agarwal; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Glenn M Chertow
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
American journal of nephrology 2013;37(3):212-22.
2013: Anne Julie Overgaard; Hans-Henrik Parving; Peter Hovind; James N McGuire; Peter Rossing; Flemming Pociot
Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients.
Journal of diabetes and its complications 2013;27(1):59-63.
2012: Hans-Henrik Parving; Frederik Persson; Marc A Pfeffer; Alexia Richard; Scott D Solomon; Zhihua Xiang; Barry M Brenner; Patrick Brunel; Nish Chaturvedi; Dick de Zeeuw; Akshay S Desai; Steven M Haffner; John J V McMurray; Maria Nicolaides
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
The New England journal of medicine 2012;367(23):2204-13.
2012: E Fagerholm; Carol Forsblom; Leif Groop; Per-Henrik Groop; A P Maxwell; A J McKnight; Maija Parkkonen; Hans-Henrik Parving; N Sandholm; A Syreeni; Lise Tarnow; E Ahlqvist
SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes.
Diabetologia 2012;55(9):2386-93.
2012: Hans-Henrik Parving; Frederik Persson; Marc A Pfeffer; Alexia Richard; Scott D Solomon; Zhihua Xiang; Juergen Armbrecht; Barry M Brenner; Nish Chaturvedi; Dick de Zeeuw; Steven M Haffner; John J V McMurray; Maria Nicolaides
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
Journal of the renin-angiotensin-aldosterone system : JRAAS 2012;13(3):387-93.
2012: Hiddo J Lambers Heerspink; Pieter A de Graeff; Frank A Holtkamp; Julia B Lewis; gerjan navis; Hans-Henrik Parving; Eberhard Ritz; Dick De Zeeuw
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers.
Kidney international 2012;82(3):330-7.
2012: Stine E Nielsen; Hans-Henrik Parving; Henrik Reinhard; Orlando M Gutiérrez; Georg Hess; Peter K Jacobsen; Myles Wolf; Dietmar Walter Zdunek; Peter Rossing
Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients.
Diabetes research and clinical practice 2012;97(1):71-6.
2012: Frederik Persson; Peter Rossing; Norman K Hollenberg; Edmund J Lewis; Julia B Lewis; Hans-Henrik Parving
Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2012;13(2):250-3.
2012: Naila Rabbani; Kasper Rossing; Peter Rossing; Lise Tarnow; Antonysunil Adaikalakoteswari; Hans-Henrik Parving; Paul J Thornalley
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
Amino acids 2012;42(5):1627-39.
2012: Stine E Nielsen; Hans-Henrik Parving; Kasper Rossing; Georg Hess; Berit R Jensen; Dietmar Walter Zdunek; Peter Rossing
The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.
Scandinavian journal of clinical and laboratory investigation 2012;72(2):137-42.
2012: Frederik Persson; Camilla Noelle Rathcke; Mari-Anne Gall; Hans-Henrik Parving; Henrik Vestergaard; Peter Rossing
High YKL-40 levels predict mortality in patients with type 2 diabetes.
Diabetes research and clinical practice 2012;96(1):84-9.
2012: Henrik Reinhard; Peter Rossing; Arnold Skimminge; Kaj Winther; Per Åkeson; E Garde; Hans-Henrik Parving; Thomas Zoëga Ramsøy; Peter K Jacobsen
Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients.
Cardiovascular diabetology 2012;11():119.
2012: Peter Lommer Kristensen; Kirsten Nørgaard; Hans-Henrik Parving; Ulrik Pedersen-Bjergaard; Hans Perrild; Henning Beck-Nielsen; Jens Sandahl Christiansen; Tonny Jensen; Birger Thorsteinsson; Lise Tarnow
A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design.
BMC endocrine disorders 2012;12():10.
2012: Henrik Reinhard; Peter Rossing; Niels Wiinberg; Kaj Winther; Peter R Hansen; Andreas Kjær; Hans-Henrik Parving; Claus L Petersen; Peter K Jacobsen
NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients.
Cardiovascular diabetology 2012;11():19.
2011: Hicham Skali; Scott D Solomon; Hajime Uno; Emmanuel Burdmann; Peter Ivanovich; sai ram keithi reddy; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick S Parfrey; Hans-Henrik Parving; Marc A Pfeffer; Ajay K Singh
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
Circulation 2011;124(25):2903-8.
2011: Claudia Cangemi; Jonas Funder; Mari-Anne Gall; Jan Erik Henriksen; Vibeke Hjortdal; Poul Flemming Høilund-Carlsen; Marie Louise Jespersen; Steen Knudsen; Torben A Kruse; Hans-Henrik Parving; Michael Kjaer Poulsen; Jan Aagard; William Scott Argraves; Peter Rossing; Vibe Skov; Waleed O Twal; Lars Melholt Rasmussen
Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes.
Clinical chemistry 2011;57(11):1556-65.
2011: Anna Syreeni; Lise Tarnow; Mark E Cooper; Assam El-Osta; Carol Forsblom; Per-Henrik Groop; Alexander P Maxwell; Amy J McKnight; Maija Parkkonen; Hans-Henrik Parving; Niina Sandholm
Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes.
Diabetes 2011;60(11):3073-80.
2011: Akshay S Desai; Kai-Uwe Eckardt; Petr Jarolim; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; John J V McMurray; Hans-Henrik Parving; Scott D Solomon; Robert Toto; Hajime Uno; Marc A Pfeffer
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2011;58(5):717-28.
2011: Lian Engelen; Isabel Ferreira; Peter Hovind; Hans-Henrik Parving; Frederik Persson; Peter Rossing; Coen D Stehouwer; Tom Teerlink; Casper G Schalkwijk
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2011;26(11):3573-7.
2011: John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Scott D Solomon; Robert M Toto; Hajime Uno; Dick de Zeeuw; Akshay S Desai; Kai-Uwe Eckardt; Peter Ivanovich; Petr Jarolim; Andrew S Levey; Eldrin F Lewis; Janet B McGill; Marc A Pfeffer
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT).
American heart journal 2011;162(4):748-755.e3.
2011: Matthew R Weir; Dion H Zappe; Norman K Hollenberg; Xiangyi Meng; Giuseppe Remuzzi; Hans-Henrik Parving
Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.
Journal of hypertension 2011;29(10):2031-7.
2011: Henrik Reinhard; Peter Rossing; Lise Tarnow; Niels Wiinberg; Kaj Winther; Andreas Kjær; Hans-Henrik Parving; Frederik Persson; Claus L Petersen; Peter R Hansen; Peter K Jacobsen
Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2011;26(10):3242-9.
2011: Merel Elise Hellemons; Stephan J L Bakker; Dick De Zeeuw; Hans-Henrik Parving; Frederik Persson; Peter Rossing; Hiddo J Lambers Heerspink
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.
Diabetes care 2011;34(9):2078-83.
2011: Frank A Holtkamp; Hans-Henrik Parving; Shahnaz Shahinfar; Merlin C Thomas; Barry M Brenner; Mark E Cooper; Pieter A de Graeff; Dick de Zeeuw; Hans J L Hillege; Hiddo J Lambers Heerspink
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
Kidney international 2011;80(3):282-7.
2011: Yan Miao; Stefan A Ottenbros; Hans-Henrik Parving; Shahnaz Shahinfar; Barry M Brenner; Mark E Cooper; Dick De Zeeuw; Diederick E Grobbee; Goos D Laverman; Hiddo J Lambers Heerspink
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Hypertension 2011;58(1):2-7.
2011: Frank A Holtkamp; Tom Berl; Pieter A de Graeff; Dick De Zeeuw; Gozewijn D Laverman; Julia B Lewis; David Packham; Hans-Henrik Parving; Giuseppe Remuzzi; Hiddo J Lambers Heerspink
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
European heart journal 2011;32(12):1493-9.
2011: Christel Joergensen; Peter Hovind; Anne Schmedes; Hans-Henrik Parving; Peter Rossing
Vitamin D levels, microvascular complications, and mortality in type 1 diabetes.
Diabetes care 2011;34(5):1081-5.
2011: Kasper Broedbaek; Trine Henriksen; Allan Weimann; Morten Petersen; Jon T Andersen; Shoaib Afzal; Espen Jimenez-Solem; Frederik Persson; Hans-Henrik Parving; Peter Rossing; Henrik E Poulsen
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.
Diabetes care 2011;34(5):1192-8.
2011: Frederik Persson; Julia B Lewis; Edmund J Lewis; Peter Rossing; Norman K Hollenberg; Hans-Henrik Parving
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Clinical journal of the American Society of Nephrology : CJASN 2011;6(5):1025-31.
2011: Anna Möllsten; Nathalie Vionnet; Carol Forsblom; Maija Parkkonen; Lise Tarnow; Samy HADJADJ; Michel Marre; Hans-Henrik Parving; Per-Henrik Groop
A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women.
Molecular genetics and metabolism 2011;103(1):66-70.
2011: Stine E Nielsen; Steen Andersen; Dietmar Walter Zdunek; Georg Hess; Hans-Henrik Parving; Peter Rossing
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.
Kidney international 2011;79(10):1113-8.
2011: Anne Katrin Sjølie; R Klein; M Porta; T Orchard; J Fuller; Hans-Henrik Parving; R Bilous; S Aldington; Nish Chaturvedi
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Diabetic medicine : a journal of the British Diabetic Association 2011;28(3):345-51.
2011: Lian Engelen; Søren S Lund; Isabel Ferreira; Lise Tarnow; Hans-Henrik Parving; Jørgen Gram; Kaj Winther; Oluf Pedersen; Tom Teerlink; Rob Barto; Coen D A Stehouwer; Allan A Vaag; Casper G Schalkwijk
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes.
European journal of endocrinology / European Federation of Endocrine Societies 2011;164(3):371-9.
2011: Johanna W Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D Stehouwer
Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
Diabetes care 2011;34(2):442-7.
2011: Søren S Lund; Martin Petersen; Merete Frandsen; Ulla M Smidt; Hans-Henrik Parving; Allan A Vaag; Tonny Jensen
Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus.
Clinical chemistry 2011;57(2):298-308.
2011: Maija Wessman; Carol Forsblom; Per-Henrik Groop; Samy HADJADJ; Tero Hiekkalinna; Jorma Ilonen; Mari A Kaunisto; Michel Marre; Alexander P Maxwell; Maija Parkkonen; Hans-Henrik Parving; Leena Peltonen; Riitta Sallinen; Jenny Söderlund; Lise Tarnow
Novel susceptibility locus at 22q11 for diabetic nephropathy in type 1 diabetes.
PloS one 2011;6(9):e24053.
2011: Henrik Reinhard; Peter Rossing; Niels Wiinberg; Kaj Winther; Peter R Hansen; Andreas Kjær; Hans-Henrik Parving; Claus L Petersen; Peter K Jacobsen
NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis.
Cardiovascular diabetology 2011;10():71.
2011: Henrik Reinhard; Peter Rossing; Niels Wiinberg; Kaj Winther; Andreas Kjær; Mads Nybo; Hans-Henrik Parving; Claus L Petersen; Lars M Rasmussen; Peter R Hansen; Peter K Jacobsen
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria.
Cardiovascular diabetology 2011;10():70.
2011: Amélie Dendooven; Lodewijk Brosens; Dongxia Li; Tri Q Nguyen; Hans-Henrik Parving; Peter Rossing; Lise Tarnow; roel goldschmeding
The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes.
Journal of negative results in biomedicine 2011;10():4.
2011: Henrik Reinhard; Lise Tarnow; Anne Sofie Astrup; Nils Billestrup; Peter Karl Jacobsen; Won Yong Kim; Maria Lajer; Thomas Mandrup-Poulsen; Hans-Henrik Parving; Nadja Pedersen; Peter Rossing
Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy.
Nephron. Clinical practice 2011;118(3):c309-14.
2011: Peter Hovind; Peter Rossing; Richard J Johnson; Hans-Henrik Parving
Serum uric acid as a new player in the development of diabetic nephropathy.
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2011;21(1):124-7.
2011: Stine Elkjaer Nielsen; Henrik Post Hansen; Bente Rona Jensen; Hans-Henrik Parving; Peter Rossing
Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study.
Nephron. Clinical practice 2011;118(2):c130-5.
2011: Y Miao; Daniela Dobre; H J Lambers Heerspink; Barry M Brenner; Mark E Cooper; Hans-Henrik Parving; Shahnaz Shahinfar; Diederick Grobbee; Dick De Zeeuw
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Diabetologia 2011;54(1):44-50.
2010: Henrik Reinhard; Maria Lajer; Mari-Anne Gall; Lise Tarnow; Hans-Henrik Parving; Lars M Rasmussen; Peter Rossing
Osteoprotegerin and mortality in type 2 diabetic patients.
Diabetes care 2010;33(12):2561-6.
2010: A Alkhalaf; Stephan J.L. Bakker; H J G Bilo; R O B Gans; gerjan navis; D Postmus; C Forsblom; P H Groop; N Vionnet; S Hadjadj; M Marre; Hans-Henrik Parving; Peter Rossing; L Tarnow
A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus.
Diabetologia 2010;53(12):2562-8.
2010: Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
Lancet 2010;376(9752):1543-51.
2010: Christian Delles; Eric Schiffer; Constantin von Zur Muhlen; Karlheinz Peter; Peter Rossing; Hans-Henrik Parving; Jane A Dymott; Ulf Neisius; Lukas U Zimmerli; Janet Snell-Bergeon; David M Maahs; Roland E Schmieder; Harald Mischak; Anna F Dominiczak
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals.
Journal of hypertension 2010;28(11):2316-22.
2010: Frederik Persson; Julia B Lewis; Edmund J Lewis; Peter Rossing; Norman K Hollenberg; Hans-Henrik Parving
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Diabetes care 2010;33(11):2304-9.
2010: S E Nielsen; K J Schjoedt; A S Astrup; L Tarnow; M Lajer; Peter Riis Hansen; Hans-Henrik Parving; Peter Rossing
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril.
Diabetic medicine : a journal of the British Diabetic Association 2010;27(10):1144-50.
2010: H Reinhard; P Karl Jacobsen; M Lajer; N Pedersen; N Billestrup; T Mandrup-Poulsen; Hans-Henrik Parving; Peter Rossing
Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes.
Diabetologia 2010;53(10):2129-33.
2010: Christel Joergensen; Mari-Anne Gall; Anne Schmedes; Lise Tarnow; Hans-Henrik Parving; Peter Rossing
Vitamin D levels and mortality in type 2 diabetes.
Diabetes care 2010;33(10):2238-43.
2010: Hiddo J Lambers Heerspink; Ron T Gansevoort; Barry M Brenner; Mark E Cooper; Hans-Henrik Parving; Shahnaz Shahinfar; Dick De Zeeuw
Comparison of different measures of urinary protein excretion for prediction of renal events.
Journal of the American Society of Nephrology : JASN 2010;21(8):1355-60.
2010: Johanna W M Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D A Stehouwer
Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
Diabetes 2010;59(8):2027-32.
2010: Frederik Persson; Peter Rossing; H Reinhard; T Juhl; C D A Stehouwer; Casper G Schalkwijk; Alexander Hessel Jan Danser; F Boomsma; E Frandsen; Hans-Henrik Parving
Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.
Diabetologia 2010;53(8):1576-80.
2010: Maria Lajer; Anders Jorsal; Lise Tarnow; Hans-Henrik Parving; Peter Rossing
Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.
Diabetes care 2010;33(7):1567-72.
2010: Stine Elkjaer Nielsen; Takeshi Sugaya; Peter Hovind; Tsuneharu Baba; Hans-Henrik Parving; Peter Rossing
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.
Diabetes care 2010;33(6):1320-4.
2010: Sten Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
BMC nephrology 2010;11():29.
2010: Maria Lajer; Inge Tarnow; Alan D Michelson; Anders Jorsal; Andrew L Frelinger; Hans-Henrik Parving; Peter Rossing; Lise Tarnow
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
Platelets 2010;21(7):525-32.
2010: Matthew R Weir; Norman K Hollenberg; Dion H Zappe; Xiangyi Meng; Hans-Henrik Parving; Giancarlo Viberti; Giuseppe Remuzzi
Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria.
Journal of hypertension 2010;28(1):186-93.
2009: Marc A Pfeffer; Emmanuel Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
The New England journal of medicine 2009;361(21):2019-32.
2009: Inge Tarnow; Alan D Michelson; Marc R Barnard; Andrew L Frelinger; Bent Aasted; Berit R Jensen; Hans-Henrik Parving; Peter Rossing; Lise Tarnow
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity.
Platelets 2009;20(7):513-9.
2009: Katrine J Schjoedt; Per K Christensen; Anders Jorsal; Frans Boomsma; Peter Rossing; Hans-Henrik Parving
Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009;24(11):3343-9.
2009: Thomas E Delea; Oleg Sofrygin; James L Palmer; Helen Lau; Veronica C Munk; Jennifer Sung; Alan Charney; Hans-Henrik Parving; Sean D Sullivan
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Journal of the American Society of Nephrology : JASN 2009;20(10):2205-13.
2009: Frederik Persson; Peter Rossing; Henrik Reinhard; Tina Juhl; Coen D A Stehouwer; Casper G Schalkwijk; Alexander Hessel Jan Danser; Frans Boomsma; Erik Frandsen; Hans-Henrik Parving
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
Diabetes care 2009;32(10):1873-9.
2009: Søren S Lund; Lise Tarnow; Anne Sofie Astrup; Peter Hovind; P K Jacobsen; A C Alibegovic; I Parving; L Pietraszek; M Frandsen; Peter Rossing; Hans-Henrik Parving; Allan Vaag
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.
Diabetes, obesity & metabolism 2009;11(10):966-77.
2009: Stine E Nielsen; takeshi sugaya; Lise Tarnow; Maria Lajer; Katrine J Schjoedt; Anne Sofie Astrup; Tsuneharu Baba; Hans-Henrik Parving; Peter Rossing
Tubular and glomerular injury in diabetes and the impact of ACE inhibition.
Diabetes care 2009;32(9):1684-8.
2009: Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Marc A Pfeffer
Dual renin-angiotensin system blockade and kidney disease.
Journal of the American College of Cardiology 2009;54(3):278-9; author reply 279-80.
2009: Rudy Bilous; Nish Chaturvedi; Anne Katrin Sjølie; John Fuller; Ronald Klein; Trevor Orchard; Massimo Porta; Hans-Henrik Parving
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Annals of internal medicine 2009;151(1):11-20, W3-4.
2009: Marc A Pfeffer; Emmanuel Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto; Hajime Uno
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
American journal of kidney diseases : the official journal of the National Kidney Foundation 2009;54(1):59-69.
2009: Peter Hovind; Peter Rossing; Lise Tarnow; Richard J Johnson; Hans-Henrik Parving
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.
Diabetes 2009;58(7):1668-71.
2009: Klaus Klausen; Hans-Henrik Parving; Henrik Scharling; Jan Skov Jensen
Microalbuminuria and obesity: impact on cardiovascular disease and mortality.
Clinical endocrinology 2009;71(1):40-5.
2009: Jennifer G Robinson; Christie M Ballantyne; Scott M Grundy; Willa A Hsueh; Hans-Henrik Parving; Jeffrey B Rosen; Adeniyi J Adewale; Adam B Polis; Joanne E Tomassini; Andrew M Tershakovec
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
The American journal of cardiology 2009;103(12):1694-702.
2009: Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Mathieu Ghadanfar; Nicole Weissbach; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009;24(5):1663-71.
2009: Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
The New England journal of medicine 2009;360(14):1395-407.
2009: Andreas Kjaer; Ulrik Sloth Kristoffersen; Lise Tarnow; Hans-Henrik Parving; Birger Hesse
Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients.
Diabetes research and clinical practice 2009;84(1):34-8.
2009: Andrew Advani; Richard E Gilbert; Kerri Thai; Renae M Gow; Robyn G Langham; Alison J Cox; Kim A Connelly; Yuan Zhang; Andrew Herzenberg; Per Knud Christensen; Carol A Pollock; Weier Qi; Sih Min Tan; Hans-Henrik Parving; Darren J Kelly
Expression, localization, and function of the thioredoxin system in diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2009;20(4):730-41.
2009: Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication].
Ugeskrift for laeger 2009;171(11):881-4.
2009: Søren S Lund; Lise Tarnow; Merete Frandsen; Bente B Nielsen; Birgitte V Hansen; Oluf Pedersen; Hans-Henrik Parving; Allan Vaag
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
BMJ (Clinical research ed.) 2009;339():b4324.
2009: Yaomin Hu; Pamela J Kaisaki; Karène Argoud; Steven P Wilder; Karin J Wallace; Peng Y Woon; Christine Blancher; Lise Tarnow; Per-Henrik Groop; Samy HADJADJ; Michel Marre; Hans-Henrik Parving; Martin Farrall; Roger D Cox; Mark Lathrop; Nathalie Vionnet; Marie-Thérèse Bihoreau; Dominique Gauguier
Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus.
BMC medical genomics 2009;2():41.
2009: Hiddo J Lambers Heerspink; R Agarwal; D W Coyne; Hans-Henrik Parving; E Ritz; Giuseppe Remuzzi; P Audhya; M J Amdahl; D L Andress; Dick De Zeeuw
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.
American journal of nephrology 2009;30(3):280-6.
2009: K J Schjoedt; A S Astrup; Frederik Persson; E Frandsen; F Boomsma; K Rossing; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.
Diabetologia 2009;52(1):46-9.
2008: A Jorsal; Lise Tarnow; Allan Flyvbjerg; Hans-Henrik Parving; Peter Rossing; L M Rasmussen
Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy.
Diabetologia 2008;51(11):2100-7.
2008: Anne Katrin Sjølie; Ronald Klein; Massimo Porta; Trevor Orchard; John Fuller; Hans-Henrik Parving; Rudy Bilous; Nish Chaturvedi
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
Lancet 2008;372(9647):1385-93.
2008: Nish Chaturvedi; Massimo Porta; Ronald Klein; Trevor Orchard; John Fuller; Hans-Henrik Parving; Rudy Bilous; Anne Katrin Sjølie
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Lancet 2008;372(9647):1394-402.
2008: David-Alexandre Trégouet; Per-Henrik Groop; Steven McGinn; Carol Forsblom; Samy HADJADJ; Michel Marre; Hans-Henrik Parving; Lise Tarnow; Ralph Telgmann; Tiphaine Godefroy; Viviane Nicaud; Rachel Rousseau; Maikki Parkkonen; Anna Hoverfält; Ivo Gut; Simon Heath; Fumihiko MATSUDA; Roger Cox; Gbenga Kazeem; Martin Farrall; Dominique Gauguier; Stefan-Martin Brand-Herrmann; François Cambien; Mark Lathrop; Nathalie Vionnet
G/T substitution in intron 1 of the UNC13B gene is associated with increased risk of nephropathy in patients with type 1 diabetes.
Diabetes 2008;57(10):2843-50.
2008: Anders Jorsal; Lise Tarnow; Jan Frystyk; Maria Lajer; Allan Flyvbjerg; Hans-Henrik Parving; Nathalie Vionnet; Peter Rossing
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.
Kidney international 2008;74(5):649-54.
2008: Henrik Leth; Kristian K Andersen; Jan Frystyk; Lise Tarnow; Peter Rossing; Hans-Henrik Parving; Allan Flyvbjerg
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes.
The Journal of clinical endocrinology and metabolism 2008;93(8):3186-91.
2008: Peter Gaede; William J Valentine; Andrew J Palmer; Daniel M D Tucker; Morten Lammert; Hans-Henrik Parving; Oluf Pedersen
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.
Diabetes care 2008;31(8):1510-5.
2008: A Jorsal; Lise Tarnow; Maria Lajer; Jakob Ek; Torben Hansen; Oluf Pedersen; Hans-Henrik Parving
The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy.
Molecular genetics and metabolism 2008;94(3):347-51.
2008: Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
The New England journal of medicine 2008;358(23):2433-46.
2008: K J Schjoedt; H P Hansen; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Long-term prevention of diabetic nephropathy: an audit.
Diabetologia 2008;51(6):956-61.
2008: Tri Q Nguyen; Lise Tarnow; Anders Jorsal; Noelynn Oliver; Peggy Roestenberg; Yasuhiko Ito; Hans-Henrik Parving; Peter Rossing; Frans A van Nieuwenhoven; roel goldschmeding
Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.
Diabetes care 2008;31(6):1177-82.
2008: Anne Sofie Astrup; Lise Tarnow; Lotte Pietraszek; Casper G Schalkwijk; Coen D A Stehouwer; Hans-Henrik Parving; Peter Rossing
Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate.
Diabetes care 2008;31(6):1170-6.
2008: Søren S Lund; Lise Tarnow; Coen D A Stehouwer; Casper G Schalkwijk; Tom Teerlink; Jørgen Gram; Kaj Winther; Merete Frandsen; Ulla M Smidt; Oluf Pedersen; Hans-Henrik Parving; Allan Vaag
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
European journal of endocrinology / European Federation of Endocrine Societies 2008;158(5):631-41.
2008: Anne Sofie Astrup; Won Yong Kim; Lise Tarnow; René M Botnar; Cheryl Simonsen; Lau Brix; Lotte Pietraszek; Peter Riis Hansen; Warren J Manning; Hans-Henrik Parving
Relation of left ventricular function, mass, and volume to NT-proBNP in type 1 diabetic patients.
Diabetes care 2008;31(5):968-70.
2008: Gowsini Joseph; Lise Tarnow; Anne Sofie Astrup; Troels Krarup Hansen; Hans-Henrik Parving; Allan Flyvbjerg; Jan Frystyk
Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients.
The Journal of clinical endocrinology and metabolism 2008;93(4):1470-5.
2008: Hans-Henrik Parving; Dick de Zeeuw; Mark E Cooper; Giuseppe Remuzzi; Nancy Liu; Jared Lunceford; Shahnaz Shahinfar; Peggy H Wong; Paulette A Lyle; Peter Rossing; Barry M Brenner
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
Journal of the American Society of Nephrology : JASN 2008;19(4):771-9.
2008: Maria Lajer; Lise Tarnow; Anders Jorsal; Tom Teerlink; Hans-Henrik Parving; Peter Rossing
Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2008;31(4):747-52.
2008: Andrew M Tershakovec; William F Keane; Zhongxin Zhang; Paulette A Lyle; Gerald B Appel; Janet B McGill; Hans-Henrik Parving; Mark E Cooper; Shahnaz Shahinfar; Barry M Brenner
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Diabetes care 2008;31(3):445-7.
2008: Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Effect of a multifactorial intervention on mortality in type 2 diabetes.
The New England journal of medicine 2008;358(6):580-91.
2008: Jakob Lykke; L Tarnow; Hans-Henrik Parving; Jannik Hilsted
A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes.
Scandinavian journal of clinical and laboratory investigation 2008;68(7):654-9.
2008: Søren S Lund; M Petersen; M Frandsen; Ulla M Smidt; Hans-Henrik Parving; Allan Vaag; T Jensen
Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus.
Scandinavian journal of clinical and laboratory investigation 2008;68(7):628-40.
2008: Søren S Lund; Lise Tarnow; Anne Sofie Astrup; Peter Hovind; Peter Karl Jacobsen; Amra Ciric Alibegovic; Ida Parving; Lotte Pietraszek; Merete Frandsen; Peter Rossing; Hans-Henrik Parving; Allan Vaag
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
PloS one 2008;3(10):e3363.
2008: Frederik Persson; Peter Rossing; Peter Hovind; Coen D A Stehouwer; Casper G Schalkwijk; Lise Tarnow; Hans-Henrik Parving
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
Scandinavian journal of clinical and laboratory investigation 2008;68(8):731-8.
2008: Søren S Lund; Lise Tarnow; Merete Frandsen; Ulla M Smidt; Oluf Pedersen; Hans-Henrik Parving; Allan Vaag
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
European journal of endocrinology / European Federation of Endocrine Societies 2008;158(1):35-46.
2008: Lise Tarnow; Per-Henrik Groop; Samy HADJADJ; Gbenga Kazeem; Francois Cambien; Michel Marre; Carol Forsblom; Hans-Henrik Parving; David Trégouët; Alexandre Thévard; Martin Farrall; Ivo Gut; Dominique Gauguier; Roger Cox; Fumihiko MATSUDA; Mark Lathrop; Nathalie Vionnet
European rational approach for the genetics of diabetic complications--EURAGEDIC: patient populations and strategy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2008;23(1):161-8.
2007: Anne Sofie Astrup; Flemming S Nielsen; Peter Rossing; Samir Ali; Jens Kastrup; Ulla Meng Smidt; Hans-Henrik Parving
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study.
Journal of hypertension 2007;25(12):2479-85.
2007: Anne Sofie Astrup; Lise Tarnow; M Christiansen; P R Hansen; Hans-Henrik Parving; Peter Rossing
Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow--up study.
Diabetic medicine : a journal of the British Diabetic Association 2007;24(12):1381-5.
2007: Maria Lajer; Lise Tarnow; Anders Jorsal; Hans-Henrik Parving
Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007;22(11):3235-9.
2007: Norman K Hollenberg; Hans-Henrik Parving; Giancarlo Viberti; Giuseppe Remuzzi; Susan Ritter; Steven Zelenkofske; Albert Kandra; William L Daley; Ricardo Rocha
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
Journal of hypertension 2007;25(9):1921-6.
2007: Annemieke M W Spijkerman; Mari-Anne Gall; Lise Tarnow; Jos W R Twisk; E Lauritzen; H Lund-Andersen; Jef J Emeis; Hans-Henrik Parving; C D A Stehouwer
Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2007;24(9):969-76.
2007: Olaf B Paulson; Hans-Henrik Parving
[Pioneering research of Niels A. Lassen].
Ugeskrift for laeger 2007;169(35):2899.
2007: Wouter B A Eijkelkamp; Zhongxin Zhang; Giuseppe Remuzzi; Hans-Henrik Parving; Mark E Cooper; William F Keane; Shahnaz Shahinfar; Gilbert W Gleim; Matthew R Weir; Barry M Brenner; Dick De Zeeuw
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Journal of the American Society of Nephrology : JASN 2007;18(5):1540-6.
2007: Søren S Lund; Lise Tarnow; C D A Stehouwer; C G Schalkwijk; M Frandsen; Ulla M Smidt; Oluf Pedersen; Hans-Henrik Parving; Allan Vaag
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
Diabetes, obesity & metabolism 2007;9(3):394-407.
2007: Samy HADJADJ; Lise Tarnow; Carol Forsblom; Gbenga Kazeem; Michel Marre; Per-Henrik Groop; Hans-Henrik Parving; François Cambien; David A Tregouet; Ivo Gut; Alexandre Théva; Dominique Gauguier; Martin Farrall; Roger Cox; Fumihiko MATSUDA; Mark Lathrop; Nathalie Hager-Vionnet
Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations.
Journal of the American Society of Nephrology : JASN 2007;18(4):1284-91.
2007: Wouter B A Eijkelkamp; Zhongxin Zhang; Barry M Brenner; Mark E Cooper; Richard B Devereux; Björn Dahlöf; Hans Ibsen; William F Keane; Lars H Lindholm; Michael H Olsen; Hans-Henrik Parving; Giuseppe Remuzzi; Shahnaz Shahinfar; Steven M Snapinn; Kristian Wachtell; Dick De Zeeuw
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.
Journal of hypertension 2007;25(4):871-6.
2007: Maria Lajer; Lise Tarnow; Steen Andersen; Hans-Henrik Parving
CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 2007;24(3):323-5.
2007: Won Yong Kim; Anne Sofie Astrup; Matthias Stuber; Lise Tarnow; Erling Falk; René M Botnar; Cheryl Simonsen; Lotte Pietraszek; Peter R Hansen; Warren J Manning; Niels T Andersen; Hans-Henrik Parving
Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy.
Circulation 2007;115(2):228-35.
2007: Peter Hovind; Steven Lamberts; Wim Hop; jaap deinum; Lise Tarnow; Hans-Henrik Parving; Joop A M J L Janssen
An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes.
European journal of endocrinology / European Federation of Endocrine Societies 2007;156(1):83-90.
2006: Frederik Persson; Peter Rossing; Peter Hovind; Coen D A Stehouwer; Casper Schalkwijk; Lise Tarnow; Hans-Henrik Parving
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
Diabetes 2006;55(12):3550-5.
2006: Andrew J Palmer; William J Valentine; Daniel M D Tucker; Joshua A Ray; Stéphane Roze; Lieven Annemans; Pablo Lapuerta; Roland Chen; Sylvie Gabriel; Paulo Carita; Roger A Rodby; Dick de Zeeuw; Hans-Henrik Parving; Maurice Laville
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Current medical research and opinion 2006;22(11):2095-100.
2006: Nathalie Vionnet; David Tregouët; Gbenga Kazeem; Ivo Gut; Per-Henrik Groop; Lise Tarnow; Hans-Henrik Parving; Samy HADJADJ; Carol Forsblom; Martin Farrall; Dominique Gauguier; Roger Cox; Fumihiko MATSUDA; Simon Heath; Alexandre Thévard; Rachel Rousseau; François Cambien; Michel Marre; Mark Lathrop
Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene.
Diabetes 2006;55(11):3166-74.
2006: Troels Krarup Hansen; Mari-Anne Gall; Lise Tarnow; Steffen Thiel; Coen D Stehouwer; Casper G Schalkwijk; Hans-Henrik Parving; Allan Flyvbjerg
Mannose-binding lectin and mortality in type 2 diabetes.
Archives of internal medicine 2006;166(18):2007-13.
2006: Lise Tarnow; Mari-Anne Gall; Birgitte V Hansen; Peter Hovind; Hans-Henrik Parving
Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes.
Diabetologia 2006;49(10):2256-62.
2006: Peter Rossing; Hans-Henrik Parving; Dick de Zeeuw
Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(9):2354-7; discussion 2357-8.
2006: Dick De Zeeuw; Hans-Henrik Parving; Robert H Henning
Microalbuminuria as an early marker for cardiovascular disease.
Journal of the American Society of Nephrology : JASN 2006;17(8):2100-5.
2006: Katrine J Schjoedt; Kasper Rossing; Tina R Juhl; Frans Boomsma; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
Kidney international 2006;70(3):536-42.
2006: Peter Karl Jacobsen; Peter Rossing; Hans-Henrik Parving
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(7):2030-1.
2006: Thomas Gardner; Birgit Sander; Michael L Larsen; Allen Kunselman; Thomas TenHave; Henrik Lund-Andersen; James Reimers; Larry Hubbard; George Blankenship; David A Quillen; Roy D Brod; Mary H Wilmarth; Henrik Post-Hansen; Hans-Henrik Parving; Matthew D Davis
An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the Astemizole Retinopathy Trial.
Current eye research 2006;31(6):535-47.
2006: Maria Lajer; Katrine J Schjoedt; P Jacobsen; Lise Tarnow; Hans-Henrik Parving
Aldosterone synthase (CYP11B2) -344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients.
Diabetic medicine : a journal of the British Diabetic Association 2006;23(6):675-80.
2006: Hans-Henrik Parving; J B Lewis; M Ravid; G Remuzzi; L G Hunsicker
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective.
Kidney international 2006;69(11):2057-63.
2006: Peter Rossing; Kasper Rossing; Peter Gaede; Oluf Pedersen; Hans-Henrik Parving
Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy.
Diabetes care 2006;29(5):1024-30.
2006: Peter Rossing; Hans-Henrik Parving
[ACE inhibitors and AT-II antagonists--do they protect against renal disease?].
Ugeskrift for laeger 2006;168(15):1564; author reply1564-5.
2006: Peter Karl Jacobsen; Lise Tarnow; Hans-Henrik Parving
Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?
Kidney international 2006;69(8):1293-5.
2006: Hans-Henrik Parving; Peter Rossing
Renoprotective effects of renin-angiotensin-system inhibitors.
Lancet 2006;367(9514):898-9; author reply 900-2.
2006: Peter Rossing; Mark E Cooper; Hans-Henrik Parving
Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes.
Diabetes care 2006;29(3):747-8; author reply 748-9.
2006: Anne Sofie Astrup; Lise Tarnow; Peter Rossing; Birgitte V Hansen; Jannik Hilsted; Hans-Henrik Parving
Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2006;29(2):334-9.
2006: Peter Gaede; Hans-Henrik Parving; Oluf Pedersen
PROactive study.
Lancet 2006;367(9504):23-4; author reply 26-7.
2006: Katrine J Schjoedt; Maria Lajer; Steen Andersen; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Scandinavian journal of clinical and laboratory investigation 2006;66(3):173-80.
2006: Lars Melholt Rasmussen; Lise Tarnow; Troels Krarup Hansen; Hans-Henrik Parving; Allan Flyvbjerg
Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients.
European journal of endocrinology / European Federation of Endocrine Societies 2006;154(1):75-81.
2006: Tri Q Nguyen; Lise Tarnow; Steen Andersen; Peter Hovind; Hans-Henrik Parving; roel goldschmeding; Frans A van Nieuwenhoven
Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2006;29(1):83-8.
2005: Katrine J Schjoedt; Kasper Rossing; Tina R Juhl; Frans Boomsma; Peter Rossing; Lise Tarnow; Hans-Henrik Parving
Beneficial impact of spironolactone in diabetic nephropathy.
Kidney international 2005;68(6):2829-36.
2005: A Sato; Lise Tarnow; Flemming S Nielsen; E Knudsen; Hans-Henrik Parving
Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment.
QJM : monthly journal of the Association of Physicians 2005;98(12):879-84.
2005: Kasper Rossing; Per K Christensen; Peter Hovind; Hans-Henrik Parving
Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients.
Diabetologia 2005;48(11):2241-7.
2005: Peter Rossing; Philip Hougaard; Hans-Henrik Parving
Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study.
Kidney international 2005;68(4):1446-50.
2005: Kasper Rossing; Katrine J Schjoedt; Ulla M Smidt; Frans Boomsma; Hans-Henrik Parving
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
Diabetes care 2005;28(9):2106-12.
2005: Anne Sofie Astrup; Lise Tarnow; Peter Rossing; Lotte Pietraszek; Peter Riis Hansen; Hans-Henrik Parving
Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study.
Kidney international 2005;68(3):1250-7.
2005: Kasper Rossing; Katrine J Schjoedt; Bente Rona Jensen; Frans Boomsma; Hans-Henrik Parving
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Kidney international 2005;68(3):1190-8.
2005: Sofia B Ahmed; Peter Hovind; Hans-Henrik Parving; Peter Rossing; Deborah A Price; Lori M B Laffel; M Cecilia Lansang; Radomir Stevanovic; Naomi D L Fisher; Norman K Hollenberg
Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy.
Diabetes care 2005;28(8):1988-94.
2005: Kasper Rossing; Mischak Harald; Hans-Henrik Parving; Per K Christensen; Michael Walden; Meike Hillmann; Thorsten Kaiser
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns.
Kidney international 2005;68(1):193-205.
2005: Steen Andersen; Frans A van Nieuwenhoven; Lise Tarnow; Peter Rossing; Kasper Rossing; Lotte Wieten; roel goldschmeding; Hans-Henrik Parving
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
Kidney international 2005;67(6):2325-9.
2005: Peter Hovind; Troels Krarup Hansen; Lise Tarnow; Steffen Thiel; Rudi Steffensen; Allan Flyvbjerg; Hans-Henrik Parving
Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study.
Diabetes 2005;54(5):1523-7.
2005: Niels Møller; Løgstrup Poulsen; Ole E Schmitz; Hans-Henrik Parving; Carl Erik Mogensen
[HbA1 and type 2 diabetes--what is optimal?].
Ugeskrift for laeger 2005;167(14):1542-3; author reply 1544.
2005: Katrine J Schjoedt; P Jacobsen; Kasper Rossing; Frans Boomsma; Hans-Henrik Parving
Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2005;37 Suppl 1():4-8.
2005: Gozewijn D Laverman; Steen Andersen; Peter Rossing; gerjan navis; Dick De Zeeuw; Hans-Henrik Parving
Renoprotection with and without blood pressure reduction.
Kidney international. Supplement 2005;(94):S54-9.
2005: Gitte Andersen; Lise Wegner; Dorit P Jensen; Charlotte Glümer; Lise Tarnow; Thomas Drivsholm; Pernille Poulsen; Sara Kristine Hansen; Eva-Maria D Nielsen; Jakob Ek; Peter Mouritzen; Allan Vaag; Hans-Henrik Parving; Knut Borch-Johnsen; Torben Jørgensen; Torben Hansen; Oluf Pedersen
PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whites.
Hypertension 2005;45(4):565-70.
2005: Anne Katrin Sjølie; Massimo Porta; Hans-Henrik Parving; Rudy Bilous; Ronald Klein
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2005;6(1):25-32.
2005: T-Christian H Mix; Robert M Brenner; Mark E Cooper; Dick de Zeeuw; Peter Ivanovich; Andrew S Levey; Janet B McGill; john mcmurray; Patrick S Parfrey; Hans-Henrik Parving; Brian J G Pereira; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Catherine Stehman-Breen; Robert D Toto; Marc A Pfeffer
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
American heart journal 2005;149(3):408-13.
2005: Hans-Henrik Parving; Peter Hovind; Peter Rossing
Telmisartan vs. enalapril in type 2 diabetes.
The New England journal of medicine 2005;352(8):835-6; author reply 835-6.
2005: Hans-Henrik Parving; C E Mogensen; M C Thomas; B M Brenner; M E Cooper
Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.
QJM : monthly journal of the Association of Physicians 2005;98(2):119-26.
2005: Peter Hovind; Lise Tarnow; Peter Rossing; Bente Rona Jensen; Malene Graae; Inge Torp; Christian Binder; Hans-Henrik Parving
[Risk factors for the development of microalbuminuria in type 1 diabetes: an incidence cohort study--a secondary publication].
Ugeskrift for laeger 2005;167(1):57-60.
2005: Lise Tarnow; Anne Sofie Astrup; Hans-Henrik Parving
Elevated placental growth factor (PlGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Scandinavian journal of clinical and laboratory investigation. Supplementum 2005;240():73-9.
2005: Peter Gaede; P Hildebrandt; G Hess; Hans-Henrik Parving; Oluf Pedersen
Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.
Diabetologia 2005;48(1):156-63.
2005: Lise Tarnow; P Hildebrandt; Birgitte V Hansen; Knut Borch-Johnsen; Hans-Henrik Parving
Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.
Diabetologia 2005;48(1):149-55.
2005: Andrew J Palmer; Lieven Annemans; Stéphane Roze; Pablo Lapuerta; Roland Chen; Sylvie Gabriel; Paulo Carita; Roger A Rodby; Dick de Zeeuw; Hans-Henrik Parving; Fernando de Alvaro
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
Kidney international. Supplement 2005;(93):S52-4.
2004: Katrine J Schjoedt; Steen Andersen; Peter Rossing; Lise Tarnow; Hans-Henrik Parving
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
Diabetologia 2004;47(11):1936-9.
2004: Peter Jacobsen; Hans-Henrik Parving
Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy.
Kidney international. Supplement 2004;(92):S108-10.
2004: Peter Gaede; Lise Tarnow; Pernille Vedel; Hans-Henrik Parving; Oluf Pedersen
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2004;19(11):2784-8.
2004: Kasper Rossing; Per K Christensen; Peter Hovind; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Progression of nephropathy in type 2 diabetic patients.
Kidney international 2004;66(4):1596-605.
2004: Peter Hovind; Lise Tarnow; Hans-Henrik Parving
Remission and regression of diabetic nephropathy.
Current hypertension reports 2004;6(5):377-82.
2004: Hans-Henrik Parving
Clinical trials report. angiotensin-converting enzyme inhibition in diabetes: above and beyond the beneficial effect of blood pressure?
Current hypertension reports 2004;6(5):366-8.
2004: Peter Hovind; Lise Tarnow; Peter Rossing; Bendix Carstensen; Hans-Henrik Parving
Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy.
Kidney international 2004;66(3):1180-6.
2004: Dick De Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steven M Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Circulation 2004;110(8):921-7.
2004: Andrew J Palmer; Lieven Annemans; Stéphane Roze; Mark Lamotte; Pablo Lapuerta; Roland Chen; Sylvie Gabriel; Paulo Carita; Roger A Rodby; Dick de Zeeuw; Hans-Henrik Parving
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
Diabetes care 2004;27(8):1897-903.
2004: Maria Lajer; Lise Tarnow; Jan Fleckner; Birgitte V Hansen; D G Edwards; Hans-Henrik Parving; Esper Boel
Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients.
Diabetic medicine : a journal of the British Diabetic Association 2004;21(8):867-73.
2004: Troels Krarup Hansen; Lise Tarnow; Steffen Thiel; Rudi Steffensen; Coen D Stehouwer; Casper G Schalkwijk; Hans-Henrik Parving; Allan Flyvbjerg
Association between mannose-binding lectin and vascular complications in type 1 diabetes.
Diabetes 2004;53(6):1570-6.
2004: Dick De Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steven M Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Kidney international 2004;65(6):2309-20.
2004: Peter Hovind; Lise Tarnow; Peter Rossing; Bente Rona Jensen; Malene Graae; Inge Torp; Christian Binder; Hans-Henrik Parving
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study.
BMJ (Clinical research ed.) 2004;328(7448):1105.
2004: Peter Jacobsen; Kasper Rossing; Hans-Henrik Parving
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Current opinion in nephrology and hypertension 2004;13(3):319-24.
2004: Hans-Henrik Parving; Steen Andersen; Peter Jacobsen; Per K Christensen; Kasper Rossing; Peter Hovind; Peter Rossing; Lise Tarnow
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
Seminars in nephrology 2004;24(2):147-57.
2004: Lise Tarnow; Peter Hovind; Tom Teerlink; Coen D A Stehouwer; Hans-Henrik Parving
Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes.
Diabetes care 2004;27(3):765-9.
2004: Birger Hesse; Christian Meyer; Flemming S Nielsen; Asako Sato; Jens D Hove; Søren Holm; Lia E Bang; Klaus F Kofoed; Tage Lysbo Svendsen; Hans-Henrik Parving; Lionel Henry Opie
Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition.
European journal of nuclear medicine and molecular imaging 2004;31(3):362-8.
2004: Mark E Molitch; Ralph DeFronzo; Marion J Franz; William F Keane; Carl Erik Mogensen; Hans-Henrik Parving; Michael W Steffes
Nephropathy in diabetes.
Diabetes care 2004;27 Suppl 1():S79-83.
2003: Steen Andersen; Jens Bröchner-Mortensen; Hans-Henrik Parving
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
Diabetes care 2003;26(12):3296-302.
2003: Peter Jacobsen; Lise Tarnow; Bendix Carstensen; Peter Hovind; Odette Poirier; Hans-Henrik Parving
Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2003;14(11):2843-50.
2003: Peter Jacobsen; Kasper Rossing; Birgitte V Hansen; P Bie; A Vaag; Hans-Henrik Parving
Effect of short-term hyperglycaemia on haemodynamics in type 1 diabetic patients.
Journal of internal medicine 2003;254(5):464-71.
2003: Garabed Eknoyan; Thomas H Hostetter; George L Bakris; Lee Hebert; Andrew S Levey; Hans-Henrik Parving; Michael W Steffes; Robert D Toto
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).
American journal of kidney diseases : the official journal of the National Kidney Foundation 2003;42(4):617-22.
2003: Steen Andersen; Peter Jacobsen; Hans-Henrik Parving
ACE insertion/deletion genotypes and angiotensin II receptor blockade in diabetic nephropathy: is there a light at the end of the tunnel?
Diabetes care 2003;26(10):2962-3.
2003: Niels Møller; Ole E Schmitz; Henrik B Mortensen; Thomas Mandrup-Poulsen; Eva E Hommel; Hans-Henrik Parving; Carl Erik Mogensen
[Insulin pumps and treatment of diabetes].
Ugeskrift for laeger 2003;165(33):3167-8; author reply 3168-9.
2003: Kasper Rossing; Peter Jacobsen; Lotte Pietraszek; Hans-Henrik Parving
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Diabetes care 2003;26(8):2268-74.
2003: Peter Gaede; Pernille Vedel Jepsen; Jens Nicolai Brink Larsen; Gunnar Vagn Jensen; Hans-Henrik Parving; Oluf Borbye Pedersen
[The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes].
Ugeskrift for laeger 2003;165(26):2658-61.
2003: Steen Andersen; Lise Tarnow; François Cambien; Peter Rossing; Tina R Juhl; jaap deinum; Hans-Henrik Parving
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Diabetes care 2003;26(5):1501-6.
2003: Peter Jacobsen; Steen Andersen; Kasper Rossing; Bente Rona Jensen; Hans-Henrik Parving
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Kidney international 2003;63(5):1874-80.
2003: Peter Hovind; Lise Tarnow; Kasper Rossing; Peter Rossing; Stefanie Eising; Nicolai Larsen; Christian Binder; Hans-Henrik Parving
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.
Diabetes care 2003;26(4):1258-64.
2003: Peter Jacobsen; Steen Andersen; Bente Rona Jensen; Hans-Henrik Parving
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2003;14(4):992-9.
2003: Peter Hovind; Peter Rossing; Lise Tarnow; Hans-Henrik Parving
Smoking and progression of diabetic nephropathy in type 1 diabetes.
Diabetes care 2003;26(3):911-6.
2003: Kasper Rossing; Per K Christensen; Steen Andersen; Peter Hovind; Henrik Post Hansen; Hans-Henrik Parving
Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.
Diabetes care 2003;26(3):569-74.
2003: Peter Jacobsen; Peter Rossing; Lise Tarnow; Peter Hovind; Hans-Henrik Parving
Birth weight--a risk factor for progression in diabetic nephropathy?
Journal of internal medicine 2003;253(3):343-50.
2003: Peter Gaede; Henrik Post Hansen; Hans-Henrik Parving; Oluf Pedersen
Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003;18(3):539-42.
2003: Steen Andersen; Peter Jacobsen; Lise Tarnow; Peter Rossing; Tina R Juhl; Hans-Henrik Parving
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003;18(2):293-7.
2003: Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
The New England journal of medicine 2003;348(5):383-93.
2003: Andreas Kjaer; Christian Meyer; Flemming S Nielsen; Hans-Henrik Parving; Birger Hesse
Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(1):19-23.
2003: Per K Christensen; Kamran Akram; Karen B Kønig; Hans-Henrik Parving
Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy.
Diabetes care 2003;26(1):156-62.
2003: Kasper Rossing; Per K Christensen; Birgitte V Hansen; Bendix Carstensen; Hans-Henrik Parving
Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Diabetes care 2003;26(1):150-5.
2003: Mark E Molitch; Ralph DeFronzo; Marion J Franz; William F Keane; Carl Erik Mogensen; Hans-Henrik Parving
Diabetic nephropathy.
Diabetes care 2003;26 Suppl 1():S94-8.
2002: Hans-Henrik Parving; Peter Hovind
Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
Current hypertension reports 2002;4(5):387-93.
2002: Lionel Henry Opie; Hans-Henrik Parving
Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection?
Circulation 2002;106(6):643-5.
2002: Steen Andersen; Peter Rossing; Tina R Juhl; jaap deinum; Hans-Henrik Parving
Optimal dose of losartan for renoprotection in diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2002;17(8):1413-8.
2002: Peter Jacobsen; Niels Grarup; Lise Tarnow; Hans-Henrik Parving; Oluf Pedersen
PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2002;17(8):1408-12.
2002: Henrik Post Hansen; Ellis Tauber-Lassen; Bente Rona Jensen; Hans-Henrik Parving
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy.
Kidney international 2002;62(1):220-8.
2002: Steen Andersen; Lise Tarnow; François Cambien; Peter Rossing; Tina R Juhl; jaap deinum; Hans-Henrik Parving
Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Kidney international 2002;62(1):192-8.
2002: Peter Jacobsen; Steen Andersen; Kasper Rossing; Birgitte V Hansen; Hans-Henrik Parving
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2002;17(6):1019-24.
2002: Peter Rossing; Philip Hougaard; Hans-Henrik Parving
Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study.
Diabetes care 2002;25(5):859-64.
2002: Coen D A Stehouwer; Mari-Anne Gall; Jos W R Twisk; Elisabeth Knudsen; Jef J Emeis; Hans-Henrik Parving
Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.
Diabetes 2002;51(4):1157-65.
2002: Per Flesner; Birgit Sander; Vibeke Henning; Hans-Henrik Parving; Morten Dornonville de la Cour; Henrik Lund-Andersen
Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications.
Acta ophthalmologica Scandinavica 2002;80(1):19-24.
2002: Kasper Rossing; P Jacobsen; EE Hommel; Elisabeth R Mathiesen; A Svenningsen; Peter Rossing; Hans-Henrik Parving
Pregnancy and progression of diabetic nephropathy.
Diabetologia 2002;45(1):36-41.
2002: Henrik Post Hansen; Peter Hovind; Bente Rona Jensen; Hans-Henrik Parving
Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy.
Kidney international 2002;61(1):163-8.
2002: Kasper Rossing; Per K Christensen; Bente Rona Jensen; Hans-Henrik Parving
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Diabetes care 2002;25(1):95-100.
2001: Per K Christensen; S Larsen; T Horn; S Olsen; Hans-Henrik Parving
Renal function and structure in albuminuric type 2 diabetic patients without retinopathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2001;16(12):2337-47.
2001: Peter Hovind; Lise Tarnow; Peter Rossing; T Teerlink; C D Stehouwer; J J Emeis; Hans-Henrik Parving
Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;38(6):1376-80.
2001: Hans-Henrik Parving
Diabetic nephropathy: prevention and treatment.
Kidney international 2001;60(5):2041-55.
2001: Peter Hovind; Peter Rossing; Lise Tarnow; H Toft; J Parving; Hans-Henrik Parving
Remission of nephrotic-range albuminuria in type 1 diabetic patients.
Diabetes care 2001;24(11):1972-7.
2001: Per K Christensen; S Lund; Hans-Henrik Parving
Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Kidney international 2001;60(4):1435-42.
2001: Peter Gaede; Pernille Vedel; Hans-Henrik Parving; Oluf Pedersen
Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2001;16(10):2028-33.
2001: Hans-Henrik Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
The New England journal of medicine 2001;345(12):870-8.
2001: Barry M Brenner; M E Cooper; Dick De Zeeuw; William F Keane; W E Mitch; Hans-Henrik Parving; Giuseppe Remuzzi; Steven M Snapinn; Zhongxin Zhang; Shahnaz Shahinfar
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
The New England journal of medicine 2001;345(12):861-9.
2001: Peter Gaede; H E Poulsen; Hans-Henrik Parving; Oluf Pedersen
Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients.
Diabetic medicine : a journal of the British Diabetic Association 2001;18(9):756-60.
2001: Lise Tarnow; Niels Grarup; Torben Hansen; Hans-Henrik Parving; Oluf Pedersen
Diabetic microvascular complications are not associated with two polymorphisms in the GLUT-1 and PC-1 genes regulating glucose metabolism in Caucasian type 1 diabetic patients.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2001;16(8):1653-6.
2001: Hans-Henrik Parving; Peter Hovind; Kasper Rossing; S Andersen
Evolving strategies for renoprotection: diabetic nephropathy.
Current opinion in nephrology and hypertension 2001;10(4):515-22.
2001: Peter Hovind; Peter Rossing; Lise Tarnow; Ulla M Smidt; Hans-Henrik Parving
Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively.
Kidney international 2001;60(1):277-83.
2001: Hans-Henrik Parving; EE Hommel; Bente Rona Jensen; Henrik Post Hansen
Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.
Kidney international 2001;60(1):228-34.
2001: Odette Poirier; Viviane Nicaud; Nathalie Vionnet; Ségolène Raoux; Lise Tarnow; H Vlassara; Hans-Henrik Parving; François Cambien
Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients.
Diabetes 2001;50(5):1214-8.
2001: Peter Rossing; L Breum; A Major-Pedersen; A Sato; H Winding; A Pietersen; J Kastrup; Hans-Henrik Parving
Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus.
Diabetic medicine : a journal of the British Diabetic Association 2001;18(3):199-205.
2001: Per K Christensen; S Lund; Hans-Henrik Parving
The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes.
Scandinavian journal of clinical and laboratory investigation 2001;61(1):43-50.
2001: Peter Hovind; Peter Rossing; Lise Tarnow; Ulla M Smidt; Hans-Henrik Parving
Progression of diabetic nephropathy.
Kidney international 2001;59(2):702-9.
2001: Henrik Post Hansen; Søren S Lund; Peter Rossing; Lise Tarnow; Flemming S Nielsen; T Jensen; Hans-Henrik Parving
Preventing diabetic nephropathy: an audit.
Scandinavian journal of clinical and laboratory investigation 2001;61(6):471-7.
2001: B Myrup; Peter Rossing; T Jensen; Hans-Henrik Parving; G Hølmer; J Gram; Cornelis Kluft; J Jespersen
Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy.
Scandinavian journal of clinical and laboratory investigation 2001;61(5):349-56.
2000: Barry M Brenner; M E Cooper; Dick De Zeeuw; Jean-Pierre Grunfeld; William F Keane; K Kurokawa; J B McGill; W E Mitch; Hans-Henrik Parving; Giuseppe Remuzzi; Artur B Ribeiro; M D Schluchter; D Snavely; Zhongxin Zhang; R Simpson; Denise Ramjit; Shahnaz Shahinfar
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
Journal of the renin-angiotensin-aldosterone system : JRAAS 2000;1(4):328-35.
2000: Henrik Post Hansen; Peter Gaede; Bente Rona Jensen; Hans-Henrik Parving
Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria.
Diabetes care 2000;23(12):1742-5.
2000: Lise Tarnow; Peter Rossing; C Jensen; Birgitte V Hansen; Hans-Henrik Parving
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2000;23(12):1725-30.
2000: S Andersen; Kristina L Blouch; Joan Bialek; M Deckert; Hans-Henrik Parving; Bryan D Myers
Glomerular permselectivity in early stages of overt diabetic nephropathy.
Kidney international 2000;58(5):2129-37.
2000: Per K Christensen; S Larsen; T Horn; S Olsen; Hans-Henrik Parving
Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy.
Kidney international 2000;58(4):1719-31.
2000: P Clausen; Peter Jacobsen; Kasper Rossing; J S Jensen; Hans-Henrik Parving; Bo Feldt-Rasmussen
Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 2000;17(9):644-9.
2000: Per K Christensen; Mari-Anne Gall; A Major-Pedersen; A Sato; Peter Rossing; L Breum; A Pietersen; J Kastrup; Hans-Henrik Parving
QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes.
Scandinavian journal of clinical and laboratory investigation 2000;60(4):323-32.
2000: Lise Tarnow; T Kjeld; E Knudsen; A Major-Pedersen; Hans-Henrik Parving
Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in type I diabetic patients.
Diabetologia 2000;43(6):794-9.
2000: Lise Tarnow; C D Stehouwer; J J Emeis; O Poirier; F Cambien; Birgitte V Hansen; Hans-Henrik Parving
Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2000;15(5):625-30.
2000: Per K Christensen; Mari-Anne Gall; Hans-Henrik Parving
Course of glomerular filtration rate in albuminuric type 2 diabetic patients with or without diabetic glomerulopathy.
Diabetes care 2000;23 Suppl 2():B14-20.
2000: Steen Andersen; Lise Tarnow; Peter Rossing; Birgitte V Hansen; Hans-Henrik Parving
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Kidney international 2000;57(2):601-6.
2000: Lise Tarnow; Peter Rossing; Flemming S Nielsen; Johan Fagerudd; O Poirier; Hans-Henrik Parving
Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2000;23(1):30-3.
1999: Casper G Schalkwijk; N Ligtvoet; H Twaalfhoven; Agnes Jager; Harriet G Blaauwgeers; Reinier O Schlingemann; Lise Tarnow; Hans-Henrik Parving; Coen D A Stehouwer; Victor W M van Hinsbergh
Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries.
Diabetes 1999;48(12):2446-53.
1999: Per K Christensen; EE Hommel; P Clausen; Bo Feldt-Rasmussen; Hans-Henrik Parving
Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies.
Kidney international 1999;56(4):1517-23.
1999: Peter Gaede; P V Jepsen; Hans-Henrik Parving; Oluf Borbye Pedersen
[Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study].
Ugeskrift for laeger 1999;161(30):4277-85.
1999: Elisabeth R Mathiesen; EE Hommel; Henrik Post Hansen; Ulla M Smidt; Hans-Henrik Parving
Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria.
BMJ (Clinical research ed.) 1999;319(7201):24-5.
1999: Flemming S Nielsen; Henrik Post Hansen; Peter Jacobsen; Peter Rossing; Ulla M Smidt; N J Christensen; Pevet P; Berthe Vivien-Roels; Hans-Henrik Parving
Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 1999;16(7):555-62.
1999: Peter Jacobsen; Kasper Rossing; Lise Tarnow; Peter Rossing; C Mallet; O Poirier; François Cambien; Hans-Henrik Parving
Progression of diabetic nephropathy in normotensive type 1 diabetic patients.
Kidney international. Supplement 1999;71():S101-5.
1999: Per K Christensen; Peter Rossing; Flemming S Nielsen; Hans-Henrik Parving
Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 1999;16(5):388-94.
1999: Lise Tarnow; S A Urhammer; B Mottlau; Birgitte V Hansen; Oluf Pedersen; Hans-Henrik Parving
The Trp64Arg amino acid polymorphism of the beta3-adrenergic receptor gene does not contribute to the genetic susceptibility of diabetic microvascular complications in Caucasian type 1 diabetic patients.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14(4):895-7.
1999: Lise Tarnow; A Sato; S Ali; Peter Rossing; Flemming S Nielsen; Hans-Henrik Parving
Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy.
Diabetes care 1999;22(3):491-4.
1999: Hans-Henrik Parving; Lise Tarnow; Flemming S Nielsen; Peter Rossing; Thomas Mandrup-Poulsen; R Osterby; Jørn Nerup
Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study.
Diabetes care 1999;22(3):478-83.
1999: Hans-Henrik Parving
Diabetic hypertensive patients. Is this a group in need of particular care and attention?
Diabetes care 1999;22 Suppl 2():B76-9.
1999: Peter Gaede; Pernille Vedel; Hans-Henrik Parving; Oluf Pedersen
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.
Lancet 1999;353(9153):617-22.
1999: Henrik Post Hansen; Per K Christensen; Ellis Tauber-Lassen; A Klausen; Bente Rona Jensen; Hans-Henrik Parving
Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy.
Kidney international 1999;55(2):621-8.
1999: A Sato; Lise Tarnow; Hans-Henrik Parving
Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy.
Diabetologia 1999;42(1):76-80.
1999: Coen D A Stehouwer; Mari-Anne Gall; Philip Hougaard; Cornelis Jakobs; Hans-Henrik Parving
Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria.
Kidney international 1999;55(1):308-14.
1998: Kasper Rossing; Peter Jacobsen; Peter Rossing; E Lauritzen; H Lund-Andersen; Hans-Henrik Parving
Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy.
Diabetes care 1998;21(11):2007-15.
1998: A Sato; Lise Tarnow; Hans-Henrik Parving
Increased left ventricular mass in normotensive type 1 diabetic patients with diabetic nephropathy.
Diabetes care 1998;21(9):1534-9.
1998: Henrik Post Hansen; Peter Rossing; Elisabeth R Mathiesen; EE Hommel; Ulla M Smidt; Hans-Henrik Parving
Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA.
Scandinavian journal of clinical and laboratory investigation 1998;58(5):405-13.
1998: Hans-Henrik Parving
Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.
Diabetologia 1998;41(7):745-59.
1998: Lise Tarnow; C Gluud; Hans-Henrik Parving
Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1998;13(5):1125-30.
1998: Flemming S Nielsen; A Sato; S Ali; Lise Tarnow; Ulla M Smidt; J Kastrup; Hans-Henrik Parving
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.
Diabetes care 1998;21(5):804-9.
1998: Peter Jacobsen; Kasper Rossing; Peter Rossing; Lise Tarnow; C Mallet; O Poirier; François Cambien; Hans-Henrik Parving
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
Kidney international 1998;53(4):1002-6.
1998: Johan Fagerudd; Lise Tarnow; P Jacobsen; S Stenman; Flemming S Nielsen; Kim Pettersson-Fernholm; Carola Grönhagen-Riska; Hans-Henrik Parving; Per-Henrik Groop
Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients.
Diabetes 1998;47(3):439-44.
1998: Peter Rossing; Philip Hougaard; K Borch-Johnsen; Hans-Henrik Parving
[Risk factors for mortality in patients with insulin-dependent diabetes].
Ugeskrift for laeger 1998;160(9):1315-9.
1997: P Clausen; Bo Feldt-Rasmussen; Peter Jacobsen; Kasper Rossing; Hans-Henrik Parving; Palle K Nielsen; U Feldt-Rasmussen; Klaus Olgaard
Microalbuminuria as an early indicator of osteopenia in male insulin-dependent diabetic patients.
Diabetic medicine : a journal of the British Diabetic Association 1997;14(12):1038-43.
1997: Henrik Post Hansen; Flemming S Nielsen; Peter Rossing; Peter Jacobsen; Bente Rona Jensen; Hans-Henrik Parving
Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.
Kidney international. Supplement 1997;63():S49-53.
1997: Per K Christensen; Henrik Post Hansen; Hans-Henrik Parving
Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients.
Kidney international 1997;52(5):1369-74.
1997: Flemming S Nielsen; Peter Rossing; Mari-Anne Gall; Ulla M Smidt; J W Chen; A Sato; Hans-Henrik Parving
Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.
Scandinavian journal of clinical and laboratory investigation 1997;57(5):427-34.
1997: Flemming S Nielsen; S Ali; Peter Rossing; Lia E Bang; Tage Lysbo Svendsen; Mari-Anne Gall; Ulla M Smidt; J Kastrup; Hans-Henrik Parving
Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 1997;14(7):538-46.
1997: Flemming S Nielsen; Peter Rossing; Mari-Anne Gall; P Skøtt; Ulla M Smidt; Hans-Henrik Parving
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Diabetes 1997;46(7):1182-8.
1997: Lise Tarnow; Flemming Pociot; PM Hansen; Peter Rossing; Flemming S Nielsen; Birgitte V Hansen; Hans-Henrik Parving
Polymorphisms in the interleukin-1 gene cluster do not contribute to the genetic susceptibility of diabetic nephropathy in Caucasian patients with IDDM.
Diabetes 1997;46(6):1075-6.
1997: Flemming S Nielsen; Peter Gaede; Pernille Vedel; Oluf Pedersen; Hans-Henrik Parving
White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy.
Diabetes care 1997;20(5):859-63.
1997: Mari-Anne Gall; Philip Hougaard; K Borch-Johnsen; Hans-Henrik Parving
Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study.
BMJ (Clinical research ed.) 1997;314(7083):783-8.
1997: Elisabeth R Mathiesen; Bo Feldt-Rasmussen; EE Hommel; T Deckert; Hans-Henrik Parving
Stable glomerular filtration rate in normotensive IDDM patients with stable microalbuminuria. A 5-year prospective study.
Diabetes care 1997;20(3):286-9.
1997: Peter Rossing; Lise Tarnow; S Boelskifte; Bente Rona Jensen; Flemming S Nielsen; Hans-Henrik Parving
Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
Diabetes 1997;46(3):481-7.
1997: Hans-Henrik Parving; Lise Tarnow; Peter Rossing
Renal protection in diabetes--an emerging role for calcium antagonists.
Cardiology 1997;88 Suppl 3():56-62.